Stockscreener 앱 받기
14.31
0.14%
-0.02
시간 외 거래:
14.31
Amicus Therapeutics Inc 주식(FOLD)의 최신 뉴스
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC - MLex
Why Amicus Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Final Week & Trade Opportunity Analysis - mfd.ru
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
Amicus Therapeutics (FOLD) to Release Earnings on Wednesday - MarketBeat
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments - MSN
BioMarin to acquire Amicus for $14.50 per share in cash, or $4.8B - MSN
Amicus Therapeutics (FOLD) Stock Analysis: Navigating Growth In Rare Disease Biotech - DirectorsTalk Interviews
Metabolism Drugs Market Booming with Rapid Growth Through 2033 | - openPR.com
New York State Common Retirement Fund Raises Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments - Yahoo Finance
Dimerix and Amicus to commercialise DMX-200 in US - MSN
Assessing Amicus Therapeutics (FOLD) Valuation After Strong 3 Month And 1 Year Shareholder Returns - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Share Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Amicus to present new data on rare disease treatments at symposium - Investing.com Canada
Amicus Therapeutics, Inc. (FOLD): Investor Outlook with a Focus on Growth and Revenue Potential - DirectorsTalk Interviews
Amicus (FOLD) Shares New Data at WORLDSymposium 2026 - GuruFocus
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026 - The Manila Times
Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN
BioMarin-Amicus file US antitrust paperwork, make EU referral request - MLex
BioMarin-Amicus US antitrust deadline set to expire on Feb. 20; EU referral sought - MLex
Top 3 Health Care Stocks That May Implode In Q1 - Benzinga
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS - Sahm
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN) - Seeking Alpha
BioMarin lines up $850m bond sale to finance Amicus takeover - The Pharma Letter
Is It Time To Reassess Amicus Therapeutics (FOLD) After Last Year’s 48.9% Gain? - simplywall.st
Y Intercept Hong Kong Ltd Sells 723,540 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin Weighs Amicus Deal And Billions In New Debt Financing - Sahm
BioMarin’s Amicus Deal Funding Reshapes Debt Load And Rare Disease Reach - Yahoo Finance
Fundamentals Check: Does BLKB meet Warren Buffetts criteriaTrade Entry Summary & Risk Controlled Daily Plans - baoquankhu1.vn
Will Amicus Therapeutics Inc. benefit from AI trends2025 Geopolitical Influence & Fast Moving Stock Watchlists - mfd.ru
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Lowered to Hold Rating by Zacks Research - MarketBeat
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating the Upside with Strategic Growth in Rare Disease Therapeutics - DirectorsTalk Interviews
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Market Recap: What is the long term forecast for Amicus Therapeutics Inc stockMarket Growth Report & Weekly High Momentum Picks - baoquankhu1.vn
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders - marketscreener.com
Amicus Therapeutics CEO Campbell sells $1.07 million in shares By Investing.com - Investing.com Canada
Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Amicus Therapeutics CEO Sells 75,000 Shares - TradingView
How the $4.8B Amicus deal with BioMarin came together - The Business Journals
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema - Finviz
Amicus Therapeutics (FOLD): Jefferies Downgrades to Hold, Lowers Price Target | FOLD Stock News - GuruFocus
Jefferies downgrades Amicus Therapeutics stock to Hold on acquisition outlook - Investing.com Canada
How A New Price Target Is Shaping The Amicus Therapeutics (FOLD) Investment Story - Yahoo Finance
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission - Finviz
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies - Finviz
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease - Yahoo Finance
Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus - TradingView
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent
Amicus Therapeutics, Inc. $FOLD Holdings Boosted by Stephens Investment Management Group LLC - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 - FinancialContent
Nordea Investment Management AB Makes New $7.84 Million Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Yahoo Finance
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Yahoo Finance
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit - Yahoo Finance
Amicus Therapeutics stock hits 52-week high at 14.36 USD By Investing.com - Investing.com Nigeria
1.12%
0.87%
자본화:
|
볼륨(24시간):